Non-vitamin K antagonist oral anticoagulants in venous thromboembolism patients: a meta-analysis of real-world studies

Zhi-Yan Liu¹, Han-Xu Zhang¹,², Ling-Yue Ma¹, Guang-Yan Mu¹, Qiu-Fen Xie¹, Shuang Zhou¹, Zi-Ning Wang¹, Zhe Wang¹, Kun Hu¹, Qian Xiang¹* and Yi-Min Cui¹,²*

Abstract

Background: The real-world studies on recurrent venous thromboembolism (VTE) and bleeding events of non-vitamin K antagonist oral anticoagulants (NOACs) in VTE patients have reported conflicting findings. Our study aimed to provide the direct comparison evidence of different NOACs for VTE patients in clinical practice settings.

Methods: Search of the medical literature was conducted using PubMed, Web of Science, EMBASE, Clinical Trials.gov, and the Cochrane Library from inception to March 22, 2021. Among the 19,996 citations retrieved, a total of 63,144 patients from 6 studies were analyzed. Clinical outcomes included recurrent VTE, death, and different bleeding events.

Results: Adjusted hazard ratio (HR) analysis suggested that apixaban had significant lower bleeding risk than rivaroxaban (major, minor and any bleeding: HR = 0.61, 0.56, 0.70; p = 0.008, < 0.0001, 0.006, respectively), but no statistics difference found in recurrent VTE events (HR = 1.02, 95% confidence interval (CI) 0.71–1.47, p = 0.93). There was no significant difference of major bleeding between dabigatran and rivaroxaban (odds ratios (OR) = 0.41, 95% CI 0.09–1.90, p = 0.25), apixaban and dabigatran (OR 0.64, 95% CI 0.15–2.72, p = 0.83). No significant difference was found in the comparison of edoxaban and other NOACs in VTE recurrence, major bleeding and composite outcome.

Conclusions: In the prevention of bleeding events, apixaban was associated with a lower risk than rivaroxaban, but equivalent efficacy for different NOACs in prevention of recurrent VTE. Evidence generated from the meta-analysis based on real-world data can help to guide selection between apixaban and rivaroxaban in routine clinical practice.

Trial registration: This systematic review and meta-analysis were conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis and Meta-analysis of Observational Studies in Epidemiology statements and was registered with PROSPERO (CRD42019140553).

Keywords: NOACs, VTE, Clinical outcomes, Direct comparison, Meta-analysis

Background

Venous thromboembolism (VTE) comprises both deep vein thrombosis (DVT) and pulmonary embolism (PE) [1]. VTE is often overlooked, and results in long-term complications including post thrombotic syndrome (PTS) for DVT, post pulmonary embolism syndrome and chronic thromboembolic pulmonary [2]. 30% of VTE individuals will develop a recurrence within 10 years of their initial event [3].

The first 3–6 months of anticoagulant treatment for VTE is generally viewed as active treatment of the initial thrombosis. Continuing anticoagulation treatment can reduce the risk of recurrent VTE but might increase
bleeding risk [4]. Heparin, the low-molecular-weight heparin (LMWHs), fondaparinux and the non-vitamin K antagonist oral anticoagulants (NOACs) are the only agents approved by the US Food and Drug Administration (FDA) recommended for the acute treatment phase. NOACs and warfarin are anticoagulation options for the long-term and extended treatment phases. The NOACs, which include the factor Xa inhibitors rivaroxaban, apixaban, and edoxaban and the direct thrombin inhibitor dabigatran, are equally efficacious for the initial treatment of VTE as compared with vitamin K antagonists and superior to placebo or aspirin for secondary VTE prevention [5–7]. An analysis of data from Danish nationwide registries in 2016 reported that 70% of patients with VTE initiated rivaroxaban, 16% initiated apixaban, 2% initiated vitamin K antagonists (VKAs), and 2% initiated dabigatran [7].

With the licensing and availability of NOACs, data are needed on their comparative safety and effective profile in many countries to guide their decision-making for patients and clinicians. The clinical trial of EINSTEIN (Oral rivaroxaban for symptomatic venous thromboembolism and oral rivaroxaban for symptomatic pulmonary embolism) and AMPLIFY (Oral apixaban for the treatment of acute venous thromboembolism) that established the safety and efficacy of rivaroxaban and apixaban were heterogeneous [8–10]. The absolute rate of recurrent VTE and bleeding were 2.1%, 1.0–1.7% in the EINSTEIN studies and 2.3%, 0.6% in the AMPLIFY study [8–10]. In contrast, Cohen et al. found that apixaban was associated with a significantly lower risk of clinically relevant non-major bleeding or major bleeding (hazard ratio (HR) 0.47, 95% CI (confidence interval) 0.36–0.61) in the network meta-analysis [11]. Head-to-head comparisons of clinical trials between different NOACs have not been done in patients with VTE [12]. Other evidence that bleeding risk may be greater with rivaroxaban than apixaban comes from network meta-analysis of phase III RCTs, which provided indirect evidence of higher major bleeding risk for rivaroxaban versus apixaban, though precision was poor [13, 14]. At present, one meta-analysis that directly compares rivaroxaban with apixaban indicated that apixaban showed equivalent efficacy in the prevention of recurrent VTE but decreased risk of major and minor bleeding events compared with rivaroxaban [15].

Observational studies that found an increased menstrual bleeding with rivaroxaban versus apixaban [16, 17], while other observational study with 8,187 VTE patients suggested no significant differences between rivaroxaban or apixaban in the risk of all-cause mortality, recurrent VTE, or hospitalized bleeding [18]. Large observational data sets may provide an opportunity to study comparative different NOACs to inform the choice among NOACs. Inconsistency based on observational research results, thus, the aim of our systematic review and meta-analysis including: (1) compare clinical outcomes between dabigatran, rivaroxaban, apixaban, and edoxaban directly in patients with VTE; (2) provide direct evidence for patients and doctors in choosing different NOACs using observational data sets.

Methods

Search strategy and study selection
Search of the medical literature was conducted using PubMed, Web of Science, EMBASE, Clinical Trials.gov, and the Cochrane Library from inception to March 22, 2021. A study was included for analysis if it met the following pre-specified criteria: (1) patients had a diagnosis of VTE, treating with NOACs (including apixaban or dabigatran or rivaroxaban or edoxaban); (2) clinical outcomes [systemic embolism (SE), VTE, bleeding or death events] were directly compared between different NOACs; (3) Clinical trials, cohort studies and case–control studies were included in the analysis; (4) Only English language and full-text articles were considered. The exclusion criteria were: (1) clinical outcomes without needed direct comparison data; (2) duplicate reports and case reports were excluded.

Citations recalled were initially screened with title and abstract (Zhiyan Liu and Hanxu Zhang), and then two investigators retrieved and assessed the full texts of potentially relevant studies for their eligibility. Any disagreement between investigators was resolved by consensus.

Outcomes assessment
Clinical outcomes included recurrent VTE, death, and different bleeding events. Different bleeding events included major bleeding, intracranial bleeding, gastrointestinal (GI) bleeding, hospitalized bleeding and minor bleeding. Definition of clinical outcomes in included studies is reported in Additional file 2: Table S1.

Data extraction and quality assessment
Details were extracted with pre-specified table on the study details, patient characteristics, drug regimes, clinical outcomes, and follow-up time, among others. The Newcastle–Ottawa Scale (NOS) was used to assess the methodological quality of included studies [19, 20]. Natural logarithms of reported hazard ratios and corresponding standard errors were extracted from studies where available. Each study with NOS scores ≥ 7 was considered as a high-quality study, whereas studies with NOS scores < 7 were considered as low-quality studies.
Assessment was performed independently by two investigators, with disagreements resolved by discussion.

**Data synthesis and statistical analyses**

Data were pooled using a random or fixed effects model to obtain a more conservative estimate of clinical outcomes of different NOACs. Measures of association in the form of odds ratios (OR) or adjusted hazard ratio (HR) were pooled, and 95% confidence interval (CI) were selected as the summary statistic. I² statistic and p-value for Q statistics were used to estimate the percentage of variability across studies that was attributable to heterogeneity. If I² > 50%, it indicates that there is high heterogeneity, and the causes of heterogeneity need to be analyzed. In case of clinical heterogeneity, subgroup analysis was performed to eliminate heterogeneity or descriptive analysis was performed; If there was no clinical heterogeneity but only statistical heterogeneity, the random effect model was used for analysis. If I² ≤ 50%, the heterogeneity is acceptable, and the fixed effect model is used for analysis.

Studies reported adjusted hazard ratio (HR) results were adjusted by multiple factors in patient characteristics (including age, gender, region, duration of follow-up, baseline bleeding status, baseline stroke status, baseline comorbidities, and baseline co-medication usage status). The p-value for statistical significance was 0.05 in all cases, except the test for heterogeneity, in which the level was set at 0.10.

Review Manager Version 5.3 (Rev Man for Windows, the Nordic Cochrane Centre, Copenhagen, Denmark) was used to generate forest plots of pooled ORs for primary outcomes with 95% CI. Both pooled HR analysis, and publication bias assessment were performed using the STATA software (version 15.3; Stata Corporation, College Station, TX, the USA).

This systematic review and meta-analysis were conducted and reported according to the Preferred Reporting Items for Systematic Reviews and Meta-analysis and Meta-analysis of Observational Studies in Epidemiology statements and was registered with PROSPERO (CRD42019140553, the Date of registration in PROSPERO was 19 September 2019, the article is a part of the study; First search time for this study was March, 2020, we conducted a supplementary search in 2021).

**Results**

40 articles were thought to be potentially eligible for inclusion after reviewing titles and abstracts among identified 19,996 citations. Finally, 63,144 VTE patients from 6 observational studies [18, 21–25] reporting the effectiveness and safety outcomes were included in the meta-analysis. All patients were Caucasian. The follow-up time for clinical outcomes ranged from 3 to 6 months. Two registered random controlled studies were found: the COBRA (NCT03266783) and CANVAS (NCT02744092) trials, which were still recruiting participants. A flow diagram of study identification and selection is shown in Fig. 1. For different research reports from the same database population, we choose the research with large time span and large population. Characteristics of the included studies are summarized in Table 1a, b. On quality assessment, 2 studies had a score of nine or eight, 2 studies had a score of seven, and 2 studies had a score of six.

**Apixaban versus rivaroxaban**

Comparison of rivaroxaban and apixaban was conducted in all included studies [18, 21–25]. Baseline comparison between different two groups is shown in Additional file 3: Table S2. No significant difference of baseline characteristics was found in comparison (p > 0.05). All patients were Caucasian. The total average age was 62.0 ± 4.47 (mean ± standard deviation (SD)) years old, with a 52.3 ± 4.45 percent of males. The mean (± SD) follow-up time for clinical outcomes was 4.50 ± 1.73 months in the comparison.

For the recurrent VTE events, no significant difference was found between apixaban (n = 3011) and rivaroxaban (n = 11,219) (OR 0.65, 95% CI 0.33–1.27, p = 0.22, Fig. 2). For major, hospitalized, intracranial, GI bleeding and death events, no difference was found among the two drugs (p > 0.05, Fig. 2). However, apixaban showed a 46% lower risk in minor bleeding (OR 0.54 95%CI 0.37–0.78, p < 0.001, Fig. 2) than that of rivaroxaban. Adjusted HR was also reported and pooled in the studies. Apixaban had significant lower bleeding (major, minor and any bleeding) risk than rivaroxaban (HR = 0.61, 0.56, 0.70; p = 0.008, < 0.0001, 0.006, respectively, Additional file 1: Figure S1). There was no statistics difference between the two groups in recurrent VTE events (HR = 1.02, 95% CI 0.71–1.47, p = 0.93, Additional file 1: Figure S1). One study [21] reported death result, showed that no different death risk existed between apixaban and rivaroxaban (HR = 1.11, 95% CI 0.87–1.41, p = 0.40, Additional file 1: Figure S1).

**Rivaroxaban versus dabigatran**

2 studies involved 923 patients reported the incidence rates of major bleeding were analyzed in comparison of rivaroxaban and dabigatran, without adjusted HR data available. There was no significant difference of major bleeding between dabigatran and rivaroxaban (OR = 0.41, 95% CI 0.09–1.90, p = 0.25, Fig. 3). Only one study [23] reported the recurrent VTE outcomes in the direct comparison of dabigatran and rivaroxaban. There are 9 and 0
patients had recurrent VTE among 844 rivaroxaban and 69 dabigatran patients.

**Apixaban versus dabigatran**

2 studies involved 444 patients reported the incidence rates of major bleeding were analyzed, without adjusted HR data available. There was no statistically difference between apixaban and dabigatran in major bleeding risk (OR=0.64, 95% CI 0.15–2.72, \( p = 0.83 \), Fig. 3). One study [24] reported the recurrent VTE outcomes in the direct comparison of apixaban and dabigatran. There are 1 and 0 patients had recurrent VTE among 344 apixaban and 69 dabigatran.

**Edoxaban versus other NOACs**

Only one study [24] reported comparison of edoxaban with other NOACs. As the limited data available, no significant difference was found in the comparison of edoxaban and other NOACs in VTE recurrence, major bleeding and composite outcome (Fig. 4).

**Sensitivity analyses and publication bias**

Formally sensitivity analysis is used when the numbers of included studies are more than 10 eligible publications, thus this study did not conduct the sensitivity analyses. No publication biases were found through the Egger’s test with \( p \) value<0.01 in comparison larger than 2 studies. For example, comparison of apixaban and rivaroxaban of recurrent VTE and major bleeding, the \( p \) value of Egger’s test was 0.394 and 0.385 respectively.

**Discussion**

After reviewing titles and abstracts, 63,144 VTE patients from 6 observational studies were included in the meta-analysis. Adjusted HR analysis suggested that apixaban had significant lower bleeding (major, minor and any bleeding) risk than rivaroxaban, but no statistics difference found in recurrent VTE events. There was no significant difference of major bleeding between dabigatran and rivaroxaban, apixaban and dabigatran. No significant difference was found in the comparison of edoxaban and other NOACs in VTE recurrence, major bleeding and composite outcome.

VTE is a common and potentially fatal disease, and the estimated a first acute VTE incidence is 0.7–1.4 per 1000 person-years [26, 27]. In addition, the socioeconomic effect of VTE is significant, with an annual cost ranging from $13.5 billion to $27.2 billion in the United States [28]. Over the past decade, NOACs have been widely used in clinical and were recommended by the 2016 American College of Chest Physicians and 2014 and 2017 European Society of Cardiology guidelines for VTE [12, 29, 30]. NOACs have several advantages over vitamin K antagonists, such as a rapid onset of action.
| Study                          | Study design  | Data sources                                                                 | Numbers | Patients | Therapy regimen | Follow-up times | Outcomes                  | NOS scales |
|-------------------------------|---------------|-------------------------------------------------------------------------------|---------|----------|----------------|-----------------|-------------------------|------------|
| (a)                           |               |                                                                               |         |          |                |                 |                         |            |
| Dawwas GK, 2018 [19]          | Retrospective | The Truven Health Market Scan commercial and Medicare Supplement claims databases in the USA between Jan 1, 2014, and Dec 31, 2016 | 15,254  | VTE      | Rivaroxaban, apixaban | 3 months         | Recurrent VTE, MB     | 8          |
| Bott-Kitslaar DM, 2019 [20]   | Prospective   | The Mayo Thrombophilia Clinic Registry between Mar 1, 2013, and Jan 30, 2018  | 600     | VTE      | Rivaroxaban, apixaban | 3 months         | Recurrent VTE, MB, CRNMB | 9          |
| Davis DO, 2017 [21]           | Retrospective | Ochsner Medical Center from January 1, 2013, through December 31, 2015        | 37      | VTE      | Dabigatran, rivaroxaban, apixaban | 6 months         | Recurrent VTE, bleeding | 6          |
| López-Núñez JJ, 2019 [22]     | Retrospective | Data in the RETE registry Jan 2013 to Apr 2018                             | 1298    | VTE      | Dabigatran, rivaroxaban, apixaban, edoxaban | 3 months         | Recurrent VTE, MB     | 6          |
| Lutsey PL, 2019 [23]          | Retrospective | Market Scan data warehouse (Truven Health Analytics) for the time-period from Jan 1, 2011 to Dec 31, 2016 | 37,768  | VTE      | Rivaroxaban, apixaban | 6 months         | Hospitalized bleeding | 7          |
| Sindet-Pedersen C, 2018 [18]  | Retrospective | Danish nationwide registries from Jan 1, 2015 to Jun 30, 2017                | 8187    | VTE      | Rivaroxaban, apixaban | 6 months         | All-cause mortality, recurrent VTE, hospitalized bleeding | 7          |

| Study                          | Race          | Apixaban                                      | Rivaroxaban                                  |
|-------------------------------|---------------|-----------------------------------------------|----------------------------------------------|
|                               |               | No Age Gender (M, %) Renal disease (%) Antiplatelets (%) | No Age Gender (M, %) Renal disease (%) Antiplatelets (%) |
| (b)                           |               |                                               |                                              |
| Dawwas GK, 2018 [19]          | Caucasian     | 3091 61.6 ± 16.4 | 49.4 | 17.1 | 7.20 | 12,163 59.9 ± 16.2 | 49.6 | 15.3 | 6.50 |
| Bott-Kitslaar DM, 2019 [20]   | Caucasian     | 302 62.4 ± 14.0 | 62.3 | 9.00 | 22.5 | 298 58.5 ± 14.2 | 52.0 | 4.00 | 20.5 |
| Davis DO, 2017 [21]           | Caucasian     | Total age: 69 ± 4.75, Gender: 45.9% male, antiplatelet 27.0% |                                              |
| López-Núñez JJ, 2019 [22]     | Caucasian     | Total age: 79 ± 9.9, Gender: 37.0% male, renal disease 41%, antiplatelet 2.0% |                                              |
| Lutsey PL, 2019 [23]          | Caucasian     | 6786 60.4 ± 16.2 | 49.6 | 13.2 | 7.00 | 30,982 56.4 ± 15.4 | 51.8 | 7.10 | 5.10 |
| Sindet-Pedersen C, 2018 [18]  | Caucasian     | 1504 70.0 ± 17.8 | 49.2 | 3.90 | 15.2 | 6683 67.0 ± 17.1 | 54.7 | 2.70 | 12.9 |

Wysokinski WE, et al. had the same population from the same database with Bott-Kitslaar DM, 2019 [20], thus this study was not included in the meta-analysis. (Wysokinski WE, Houghton DE, Casanegra AI, et al. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism. Am J Hematol. 2019;94(11):1185-1192. https://doi.org/10.1002/ajh.25604)

VTE venous thromboembolism, SE systemic embolism, MB major bleeding, GI gastrointestinal, CRNMB clinically relevant nonmajor bleeding, NOS Newcastle–Ottawa Scale
and predictable pharmacokinetic profile. This allows for simplified drug administration in a standardized dose and avoids the need for laboratory monitoring and dose adjustments [31]. Without direct comparison of NOACs with one another in clinical trials, the choice for one drug over another are based on different treatment regimens, patient characteristics, and patient preference [31].

Recurrent VTE and bleeding events are the most feared complication in patients receiving anticoagulant therapy for VTE. Therefore, the clinical outcomes of different drugs are also an important factor in drug selection.
Fig. 3 Comparison of dabigatran and rivaroxaban in different clinical outcomes
Cohen et al. [32] reported no difference in the risk of recurrent VTE between apixaban and rivaroxaban by indirectly assessed the efficacy and safety of NOACs (by comparing apixaban and rivaroxaban against standard therapy). Another meta-analysis [13] found no significant difference between apixaban and rivaroxaban (RR=0.57, 95% CI 0.29–1.15) in the risk of recurrent VTE. These results are in line with our findings in the direct comparison. An observational study directly comparing the efficacy and safety of NOACs used for the treatment of VTE reported that apixaban and rivaroxaban therapy was associated with similar rates of VTE recurrence and major bleeding, with a lower rate of minor with apixaban [22]. However, another observational study [21] found that the use of apixaban compared with rivaroxaban was associated with decreased risk of recurrent VTE (HR=0.37, 95% CI 0.24–0.55, p<0.0001) and major bleeding events (HR=0.54, 95% CI 0.37–0.82, p=0.0031) in the multivariable Cox regression models. Results from two randomized controlled trials comparing apixaban and rivaroxaban head to head, the COBRA (NCT03266783) and CANVAS (NCT02744092) trials, which are still recruiting participants, are awaited. Before these results become available, evidence generated from the meta-analysis based on real-world data can help to guide selection between apixaban and rivaroxaban in routine clinical practice.

Compared with the published meta that directly compares rivaroxaban with apixaban [15], this study added comparison of dabigatran and rivaroxaban, apixaban and dabigatran, edoxaban and other NOACs. And this study suggested that no difference found in different NOACs, but lower bleeding (major, minor and any bleeding) risk of apixaban than rivaroxaban.

Our study has several strengths and limitations. First, this is a meta-analysis assessment, based on data from routine clinical practice of clinical outcomes of different NOACs in patients with VTE. Second, in addition to the comparison of the crude data, we also carried out a pooled analysis of the adjusted HR data analysis. Adjusted HR results were adjusted by multiple factors in patient characteristics. Therefore, the results of the

---

### Other NOACs vs. edoxaban

| study               | comparison        | event1 | total1 | event2 | total2 | OR (95% CI)   |
|--------------------|-------------------|--------|--------|--------|--------|---------------|
| López-Núñez JJ, 2019 | apixaban-edoxaban | 6      | 344    | 0      | 41     | 1.57 (0.09, 28.30) |
| López-Núñez JJ, 2019 | rivaroxaban-edoxaban | 10   | 844    | 0      | 41     | 1.03 (0.06, 17.91) |
| López-Núñez JJ, 2019 | dabigatran-edoxaban | 2     | 69     | 0      | 41     | 2.99 (0.14, 63.71) |

### Composite outcome

| study               | comparison        | event1 | total1 | event2 | total2 | OR (95% CI)   |
|--------------------|-------------------|--------|--------|--------|--------|---------------|
| López-Núñez JJ, 2019 | apixaban-edoxaban | 7      | 344    | 0      | 41     | 1.81 (0.10, 32.21) |
| López-Núñez JJ, 2019 | rivaroxaban-edoxaban | 18   | 844    | 0      | 41     | 1.82 (0.11, 30.70) |
| López-Núñez JJ, 2019 | dabigatran-edoxaban | 2     | 69     | 0      | 41     | 2.99 (0.14, 63.71) |

### VTE recurrence

| study               | comparison        | event1 | total1 | event2 | total2 | OR (95% CI)   |
|--------------------|-------------------|--------|--------|--------|--------|---------------|
| López-Núñez JJ, 2019 | apixaban-edoxaban | 1      | 344    | 0      | 41     | 0.36 (0.01, 9.02) |
| López-Núñez JJ, 2019 | rivaroxaban-edoxaban | 9    | 844    | 0      | 41     | 0.93 (0.05, 16.32) |
| López-Núñez JJ, 2019 | dabigatran-edoxaban | 0     | 69     | 0      | 41     | (Excluded) |

**Fig. 4** Comparison of edoxaban and other NOACs in different clinical outcomes
analysis are more reliable than those of conventional observational studies, excluding the influence of some confounding factors. Limitations of this study include the limited studies and relatively small sample size of patients involved in the comparison of dabigatran with other NOACs. Furthermore, no specific dose groups were distinguished in drug comparison of included studies, so comparison between specific doses could not be obtained. In addition, we restricted our search to English language, we might miss some studies.

Conclusion
Our study is unique and distinguished by its ability to directly compare multiple NOACs with 63,144 VTE patients. In the prevention of bleeding events, apixaban was associated with a lower risk than rivaroxaban, but equivalent efficacy for different NOACs in prevention of recurrent VTE. Evidence generated from the meta-analysis based on real-world data can help to guide selection between apixaban and rivaroxaban in routine clinical practice.

Abbreviations
CI: Confidence interval; DVT: Deep vein thrombosis; GI: Gastrointestinal; HR: Hazard ratio; LMWHs: Low-molecular-weight heparin; NOACs: Non-vitamin K antagonist oral anticoagulants; NOS: Newcastle–Ottawa Scale; VTE: Venous thromboembolism; OR: Odds ratios; PE: Pulmonary embolism; PTS: Post-thrombotic syndrome; SE: Systemic embolism; SD: Standard deviation; VKAs: Vitamin K antagonists.

Supplementary Information
The online version contains supplementary material available at https://doi.org/10.1186/s12872-022-02550-8.

Additional file 1. Figure S1. Comparison of apixaban and rivaroxaban in different clinical outcomes.

Additional file 2. Definition of clinical outcomes in the study.

Additional file 3. Table S2. Baseline comparison between different two groups.

Acknowledgements
Not applicable.

Authors' contributions
YMC and QX conceived and designed the study. ZYL and HXZ searched the databases and checked these according to the eligible criteria and exclusion criteria. HKZ, GYM helped develop search strategies. LYM, ZNW and SZ distinguished in drug comparison of included studies, so comparison between specific doses could not be obtained. In addition, we restricted our search to English language, we might miss some studies.

Availability of data and materials
All data generated or analysed during this study are included in this published article. Zhiyan Liu (email liuzhiyan09@163.com) can be contacted if someone wants to request the data from this study.

Declarations

Ethical approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
The authors declare no competing interests.

Author details
1Department of Pharmacy, Peking University First Hospital, No. 6, Dahongluochang Street, Xicheng District, Beijing 100034, China. 2School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China.

Received: 4 October 2021 Accepted: 4 March 2022

Published online: 14 March 2022

References
1. Goldhaber SZ, Bounameaux H. Pulmonary embolism and deep vein thrombosis. Lancet. 2012;379:1835–46.
2. Klok FA, van der Hulle T, den Exter PL, Lankeit M, Huisman MV, Koster S. The post-PE syndrome: a new concept for chronic complications of pulmonary embolism. Blood Rev. 2014;28:221–6.
3. WRITING GROUP MEMBERS, Lloyd-Jones D, Adams RJ, Brown TM, Carnethon M, Dai S, De Simone G, Ferguson TB, Ford E, Furie K, Gillespie C, Go A, Greenlund K, Haase N, Hailpern S, Ho PM, Howard V, Kissela B, Kittner S, Lackland D, Lisabeth L, Marelli A, McDermott MM, Meigs J, Mozaffarian D, Mussolino M, Nichol G, Roger VL, Rosamond W, Sacco R, Sorlie P, Roger VL, Thom T, Wunderlich SM, Wong ND, Wylie-Rosett J. American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics-2010 update: a report from the American Heart Association Circulation. 2010;121:46–215.
4. Weitz JI, Lensing AWA, Prins MH, Bauersachs R, Beyer-Westendorf J, Bouna­rneaux H, Brown TL, Cohain A, Cohen AT, Davidson BL, Decousus H, Ferrand MB, Fuster V, Goldhaber SZ, Hylek EM, Kakkar AK, Hernandez AV, Hirsh J, Holberg G, Kakkar AK, Haskell L, van Bellen B, Pap AF, Berkowitz SD, Verhamme P, Wells PS, Prandoni P, EINSTEIN CHOICE Investigators. Rivaroxaban or aspirin for extended treatment of venous thromboembolism. N Engl J Med. 2017;376:1211–2.
5. Adam SS, McDuffi JR, Ortel TL, Williams JW Jr. Comparative effectiveness of warfarin and new oral anticoagulants for the management of atrial fibrillation and venous thromboembolism: a systematic review. Ann Intern Med. 2012;157:796–807.
6. Lee LH. DOACs-advances and limitations in real world. Thromb J. 2016;14(suppl 1):17.
7. Sindet-Pedersen C, Pallisgaard JD, Skaer L, Berger JS, Lamberts M, Torp-Pedersen C, Grisdale GH, Olesen JB. Temporal trends in initiation of VKA, rivaroxaban, apixaban and dabigatran for the treatment of venous thromboembolism—a Danish nationwide cohort study. Sci Rep. 2017;7:3347.
8. Agnelli G, Buller HR, Cohen A, Curto M, Gallus AS, Johnson M, Masiukiewicz U, Pak R, Thompson J, Raskob GE, Weitz JI. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799–808.
9. Buller HR, Prins MH, Lensin AW, Decousus H, Jacobson BF, Minar E, Chlumsky J, Verhamme P, Wells PS, Agnelli G, Cohen A, Berkowitz SD, Bouna­rneaux H, Davidson BL, Misselwitz F, Gallus AS, Raskob GE, Schellong S, Segers A. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287–97.
10. Bauersachs R, Berkowitz SD, Brenner B, Buller HR, Decousus H, Gallus AS, Lensing AW, Misselwitz F, Prins MH, Raskob GE, Segers A, Verhamme P, Wells PS, Agnelli G, Bouna­rneaux H, Cohen A, Davidson BL, Piwowar F, Liu et al. BMC Cardiovascular Disorders (2022) 22:105

Author details
1 Department of Pharmacy, Peking University First Hospital, No. 6, Dahongluochang Street, Xicheng District, Beijing 100034, China. 2 School of Pharmaceutical Sciences, Peking University Health Science Center, Beijing, China.
Schellong S. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499–510.

11. Cohen AT, Hamilton M, Bird A, Mitchell SA, Li S, Horblyuk R, Batson S. Comparison of the non-VKA oral anticoagulants apixaban, dabigatran, and rivaroxaban in the extended treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS ONE. 2016;11:e0160064.

12. Kearon C, Akl EA, Ornelas J, Blaivas A, Jimenez D, Bounameaux H, Husman M, King CS, Morris TA, Sood N, Stevens SM, Vintch JRE, Wells P, Woller SC, Moores L. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149:315–52.

13. Mantha S, Ansell J. Indirect comparison of dabigatran, rivaroxaban, apixaban and edoxaban for the treatment of acute venous thromboembolism. J Thromb Thrombolysis. 2015;39:155–65.

14. Sterne JA, Bodalia PN, Bryden PA, López-López JA, Okoli GN, Thorn HH, Caldwell DM, Dias S, Eaton D, Higgins JP, Hollingworth W, Salisbury C, Savovic J, Sofat R, Stephenson Boal A, Welton NJ, Hingorani AD. Oral anticoagulants for primary prevention, treatment and secondary prevention of venous thromboembolic disease, and for prevention of stroke in atrial fibrillation: systematic review, network meta-analysis and cost-effectiveness analysis. Health Technol Assess. 2017;21:1–386.

15. Aryal MR, Gosain R, Donato A, et al. Systematic review and meta-analysis of the efficacy and safety of apixaban compared to rivaroxaban in acute VTE in the real world. Blood Adv. 2019;3(15):2381–7.

16. Myers B, Webster A. Heavy menstrual bleeding on rivaroxaban—comparison with apixaban. Br J Haematol. 2016;176:833–5.

17. Norby FL, Alonso A. Comparative effectiveness of rivaroxaban in the treatment of nonvalvular atrial fibrillation. J Comp Eff Res. 2017;6:549–60.

18. Sinders-Pedersen C, Stærk L, Pallisgaard JL, Gerds TA, Berger JS, Torp-Pedersen C, Grilason GH, Ollesen JB. Safety and effectiveness of rivaroxaban and apixaban in patients with venous thromboembolism: a nationwide study. Eur Heart J Cardiovasc Pharmacother. 2018;4:220–7.

19. Oremus M, Oremus C, Hall GB, McKinnon MC, Cognition Systematic Review Team. Inter-rater and test-retest reliability of quality assessments by novice student raters using the Jadad and Newcastle-Ottawa Scales. BMJ Open. 2012;2:1368.

20. Sanderson S, Tatt B, Higgins JP. Tools for assessing quality and susceptibility to bias in observational studies in epidemiology: a systematic review and annotated bibliography. Int J Epidemiol. 2007;36:666–76.

21. Dawwas GK, Brown J, Dietrich E, Park H. Effectiveness and safety of apixaban versus rivaroxaban for prevention of recurrent venous thromboembolism and adverse bleeding events in patients with venous thromboembolism: a retrospective population-based cohort analysis. Lancet Haematol. 2019;6:20–8.

22. Bott-Kitslaar DM, McBane RD, Casanegra AJ, Houghton DE, Froehling DA, Vlazny DT, Ashrani AA, Hodge DO, Vargas ER, Bartlett MA, Saadiq RA, Daniels PR, Shields RC, Lenz CJ, Lang TR, Wysokinski WE. Apixaban and rivaroxaban in patients with acute venous thromboembolism. Mayo Clin Proc. 2019;94:242–52.

23. Davis DO, Davis KA. Evaluation of direct-acting oral anticoagulant use in patients with cancer. J Pharm Pract. 2018;31:441–4.

24. López-Núñez JJ, Pérez-Andrés R, Di Micco P, Schellong S, Gómez-Cuervo C, Sahuquillo JC, Ciammaichella M, Morales MDV, Bosevski M, Monreal M, and the RETE Investigators. Direct oral anticoagulants or standard anticoagulant therapy in fragile patients with venous thromboembolism. TH Open. 2019;3:67–76.

25. Lutsey PL, Zakai NA, MacLehose RF, Norby FL, Walker RF, Roetker NS, Adam TJ, Alonso A. Risk of hospitalised bleeding in comparison of oral anticoagulant options for the primary treatment of venous thromboembolism. Br J Haematol. 2019;185:903–11.

26. Tagalakis V, Patenaude V, Kahn SR, Sussa S. Incidence of and mortality from venous thromboembolism in a real-world population: the Q-VTE study cohort. Am J Med. 2013;126:832.

27. Huang W, Goldberg RJ, Anderson FA, Kiefte CI, Spencer FA. Secular trends in occurrence of acute venous thromboembolism: the Worcester VTE Study (1985–2009). Am J Med. 2014;127:829–39.

28. Mahan CE, Bonego ME, Woensching AL, Fedenci R, Downey R, Tiongson J, Bieniarz MC, Cavanaugh BJ, Spyropoulos AC. Venous thromboembolism annualized United States models for total, hospital-acquired and preventable costs utilizing long-term attack rates. Thromb Haemost. 2012;108:291–302.

29. Konstantinides SV, Torbicki A, Agnelli G, Task Force for the Diagnosis and Management of Acute Pulmonary Embolism of the European Society of Cardiology, et al. 2014 ESC guidelines on the diagnosis and management of acute pulmonary embolism. Eur Heart J. 2014;35:3033–69.

30. Mazzoli L, Aboyans V, Agnozo W, Agnelli G, Alatri A, Bauersachs R, Brekelmans MPA, Buller HR, Blas A, Farge D, Konstantinides S, Palareti G, Prandoni P, Righini M, Torbicki A, Vlachopoulos C, Brodmann M. Diagnosis and management of acute deep vein thrombosis: a joint consensus document from the European Society of Cardiology working groups of aorta and peripheral vascular diseases and pulmonary circulation and right ventricular function. Eur Heart J. 2018;39:4208–18.

31. Tischler T, Kraljipol J, Le Gal G, Wells PS. Venous thromboembolism: advances in diagnosis and treatment. JAMA. 2018;320:1583–94.

32. Cohen AT, Hamilton M, Mitchell SA, Phatak H, Liu X, Bird A, Tushabe D, Batson S. Comparison of the novel oral anticoagulants apixaban, dabigatran, edoxaban, and rivaroxaban in the initial and long-term treatment and prevention of venous thromboembolism: systematic review and network meta-analysis. PLoS ONE. 2015;10:e0144856.

Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Ready to submit your research? Choose BMC and benefit from:
- fast, convenient online submission
- thorough peer review by experienced researchers in your field
- rapid publication on acceptance
- support for research data, including large and complex data types
- gold Open Access which fosters wider collaboration and increased citations
- maximum visibility for your research: over 100M website views per year

At BMC, research is always in progress.
Learn more: biomedcentral.com/submissions